Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care. 

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

Radiation therapy produced superior HRQOL outcomes and fewer toxicities vs endocrine therapy in older patients with stage I luminal-like breast cancer.

Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer

Ultra-sensitive tissue-free ctDNA testing showed that baseline ctDNA was associated with larger pathological tumor size in HR-positive breast cancer.

Baseline ctDNA Is Associated With Larger Pathological Tumors in HR+ Early Breast Cancer

Elacestrant increased real-world TTNT for patients with ESR1-mutant HR-positive/HER2-negative breast cancer vs PFS from the phase 3 EMERALD trial. 

Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for 

. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Glofitamab generated high response rates and durable remissions in R/R mantle cell lymphoma, including high-risk subgroups, with sustained MRD negativity.

Glofitamab Produces Durable Remissions in R/R Mantle Cell Lymphoma

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Tracy I. George, MD, discusses how ultra-sensitive duplex sequencing expands diagnostic capabilities in ISM by improving the detection of KIT mutations. 

Ultra-Sensitive Duplex Sequencing Improves Diagnostic Capabilities in Indolent Systemic Mastocytosis

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Stacey A. Cohen, MD, provides an overview on the current landscape of immunotherapies and prognostic tools in the treatment of colorectal cancer.

ctDNA, Neoadjuvant Immunotherapy Combos Could Help Reshape Management of CRC

A new treatment is showing promise for people with high-risk smoldering multiple myeloma

Research Shows New Treatment Could Delay Cancer Progression in Patients With High-Risk Smoldering Multiple Myeloma

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

My Treatment Approach: Optimizing Treatment for Chronic GVHD

Video Series

Clinical

Considerations for Third-Line Treatment in Chronic GVHD

Video content above is prompted by the following:

 For patients showing inadequate response to second-line therapies, what factors guide your treatment selection in third line and beyond?

Please discuss the role of safety concerns, organ involvement, severity, etc, in your decision to use one agent over another.

Videos

This educational program, led by experts Shernan Holtan, MD, and Haris Ali, MD, explores the latest strategies and emerging treatments for optimizing management of chronic graft-vs-host disease (cGVHD), including monitoring techniques, therapeutic options, and patient-reported outcomes.

After a brief introduction, Shernan Holtan, MD, and Haris Ali, MD, discuss the distinction between acute and chronic graft-vs-host disease. 

Differentiating Acute and Chronic Graft-vs-Host Disease

Medical experts discuss navigating chronic GVHD.

Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring

Medical experts discuss overall goals for cGVHD treatment as well as concerns with long-term corticosteroid use in treatment. 

Optimizing Chronic GVHD Therapy

Medical experts discuss criteria for switching GVHD treatments and how to choose between available treatment options. 

Navigating Treatment Decisions in Chronic GVHD

Medical experts discuss advanced therapies in cGVHD. 

Overview of Advanced Therapies in cGVHD

Medical experts discuss the data that led to belumosudil’s FDA approval. 

Overview of the ROCKstar Study

Medical experts discuss considerations for third-line treatment in chronic GVHD. 

Medical experts discuss treatment selection for a specific clinical scenario. 

Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD

Medical experts discuss the recent updates presented at ASH 2023 and TANDEM 2024. 

Recent Updates: REACH3, ROCKstar, and RWD

Medical experts discuss the mechanism of action within axatilimab. 

AGAVE-201: Axatilimab for cGVHD

Medical experts discuss emerging trends in chronic GVHD treatment. 

Emerging Trends in Chronic GVHD: Promising Clinical Trials and the Future Treatment Landscape

Medical experts discuss the role of patient-reported outcomes in cGVHD. 

Clinical Impact of Patient-Reported Outcomes in cGVHD

Medical experts discuss multidisciplinary approaches to GVHD. 

Considerations for Third-Line Treatment in Chronic GVHD

EP: 1.Differentiating Acute and Chronic Graft-vs-Host Disease

EP: 2.Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring

EP: 3.Optimizing Chronic GVHD Therapy

EP: 4.Navigating Treatment Decisions in Chronic GVHD

EP: 5.Overview of Advanced Therapies in cGVHD

EP: 6.Overview of the ROCKstar Study

EP: 7.Considerations for Third-Line Treatment in Chronic GVHD

EP: 8.Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD

EP: 9.Recent Updates: REACH3, ROCKstar, and RWD

EP: 10.AGAVE-201: Axatilimab for cGVHD

EP: 11.Emerging Trends in Chronic GVHD: Promising Clinical Trials and the Future Treatment Landscape

EP: 12.Clinical Impact of Patient-Reported Outcomes in cGVHD

EP: 13.Multidisciplinary Approaches to GVHD

Latest Conference Coverage